Summary
• IM Cannabis Corp. shares rose 5.68% to $1.86 after-hours following the announcement of CFO Asi Levi’s appointment.
• Levi, with over 15 years of experience, aims to strengthen the company’s financial leadership amid growth in Israel and Germany.
• Analysts maintain an overall “Buy” rating for IM Cannabis, reflecting optimism about the company’s strategic financial direction.
IM Cannabis Corp. (NASDAQ: IMCC) experienced a rise in after-hours trading, increasing 5.68% to $1.86, up from the previous close of $1.76. This uptick appears to be linked to the recent appointment of new CFO Asi Levi, which has sparked interest among investors.
CFO Appointment Sparks Investor Interest
The notable price movement follows the announcement made on December 12, 2025, regarding the appointment of Asi Levi as Chief Financial Officer, effective immediately. Levi brings over 15 years of financial experience, having previously held significant positions in various companies, including Water Ways Technologies Inc. and DekelOil CI. His appointment comes as IM Cannabis seeks to strengthen its financial leadership amidst its operational growth in Israel and Germany.
In the last earnings report, IM Cannabis significantly surprised analysts with a current EPS of -0.54, which was far below the estimate of -0.02, marking an unexpected variance of 2214%. The company’s past performance reflected a progressive shift, although it also pointed to challenges, with the previous EPS being -0.07.
Trading Setup: Performance Metrics and Volatility
Looking at the broader market context, IMCC’s recent movement reflects a notable recovery trend following a challenging year, as the stock has seen a year-to-date decline of 24.5% and a three-year drop of 98.5%. However, the stock displayed monthly resilience, with performance growing by 76.3%.
Currently, the stock has an RSI of 54.3, indicating a moderately bullish sentiment among traders. Additionally, the average trading volume over the past three months sits at approximately 526,500 shares, with recent trading showing volume around 23,940 shares, reflecting routine market engagement following the CFO’s announcement.
Analyst Ratings Signal Optimism
The consensus among analysts remains optimistic, with an overall “Buy” rating for IM Cannabis Corp. This sentiment may further buoy investor confidence in light of the recent management changes aimed at enhancing the company’s strategic financial oversight.
Closing Thoughts
With the latest leadership update now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session. The positive reaction to the CFO appointment could signal a shift in sentiment as traders evaluate the company’s future growth prospects.